Effects of a high-selenium yeast supplement on celecoxib plasma levels: a randomized phase II trial.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D016588:Anticarcinogenic Agents / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D000068579:Celecoxib; D015179:Colorectal Neoplasms / Q000517:prevention & control*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004347:Drug Interactions; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011720:Pyrazoles; D012441:Saccharomyces cerevisiae / Q000737:chemistry*; D012643:Selenium / Q000008:administration & dosage / Q000494:pharmacology*; D013449:Sulfonamides / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D015430:Weight Gain
D016588:Anticarcinogenic Agents; D011720:Pyrazoles; D013449:Sulfonamides; D012643:Selenium; D000068579:Celecoxib